Peripheral Opioid Receptors in the Gut Can Independently Slow Digestion
Gut opioid receptors can independently slow transit — and a peptide blocker reversed constipation without affecting brain-based pain relief.
Quick Facts
What This Study Found
Peripheral mu-opioid receptors in the gut can independently slow gastrointestinal transit. The peptide agonist PL017 slowed gut transit at 0.37 mg/kg but did not produce pain relief until 30 mg/kg, about 80 times higher. This proves gut mu receptors work independently of brain receptors.
Delta and kappa opioid receptors in the gut also slowed transit, but less powerfully than mu receptors.
The key finding: a peptide opioid antagonist that cannot cross the blood-brain barrier blocked morphine's gut-slowing effect without reducing its painkilling activity. This pharmacological separation means constipation and pain relief work through different receptor populations (gut vs brain).
Key Numbers
How They Did This
Mice received subcutaneous opioid agonists selective for mu, delta, and kappa receptors. Gastrointestinal transit was measured by tracking a charcoal meal through the gut. Pain was measured using the hot-plate test. Brain-impermeant peptide antagonists were given to separate central from peripheral effects. Multiple receptor types and routes of administration were tested.
Why This Research Matters
Constipation is the most common side effect of opioid painkillers. This study proved constipation is caused by gut receptors, not brain receptors. This finding led directly to the development of peripheral opioid antagonists like methylnaltrexone (Relistor), which is now FDA-approved to treat opioid-induced constipation without reducing pain relief.
The Bigger Picture
Opioid-induced constipation affects millions of pain patients. This study showed it can be blocked peripherally without losing pain relief — the concept behind drugs like methylnaltrexone (Relistor).
What This Study Doesn't Tell Us
Tested in mice, not people. The blood-brain barrier permeability of peptide antagonists may differ between mice and humans. Only acute dosing was studied. Chronic opioid use may change the peripheral/central balance.
Questions This Raises
- ?Could peripheral opioid antagonists be combined with all opioid pain medications?
- ?Are there other peripheral opioid side effects that can be similarly separated?
Trust & Context
- Key Stat:
- Constipation separable from analgesia Using a peripheral-only opioid antagonist
- Evidence Grade:
- Moderate animal study with clear pharmacological separation of peripheral vs central opioid effects.
- Study Age:
- Published in 1987 — this concept led to development of approved peripheral opioid antagonists like methylnaltrexone.
- Original Title:
- Peptide opioid antagonist separates peripheral and central opioid antitransit effects.
- Published In:
- The Journal of pharmacology and experimental therapeutics, 243(2), 492-500 (1987)
- Authors:
- Shook, J E, Pelton, J T, Hruby, V J(3), Burks, T F
- Database ID:
- RPEP-00059
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why do opioids cause constipation?
Opioid receptors in the gut wall slow muscle contractions and fluid secretion. This is separate from the brain-based pain relief — the gut has its own opioid receptor system.
Are there drugs that fix this?
Yes — methylnaltrexone (Relistor) and similar drugs block opioid receptors only in the gut, relieving constipation without reducing pain control. This study helped establish the concept.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00059APA
Shook, J E; Pelton, J T; Hruby, V J; Burks, T F. (1987). Peptide opioid antagonist separates peripheral and central opioid antitransit effects.. The Journal of pharmacology and experimental therapeutics, 243(2), 492-500.
MLA
Shook, J E, et al. "Peptide opioid antagonist separates peripheral and central opioid antitransit effects.." The Journal of pharmacology and experimental therapeutics, 1987.
RethinkPeptides
RethinkPeptides Research Database. "Peptide opioid antagonist separates peripheral and central o..." RPEP-00059. Retrieved from https://rethinkpeptides.com/research/shook-1987-peptide-opioid-antagonist-separates
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.